United States · Investor

Invus

Last cheque observed Oct 2026; 148 cheques on record.

Deploying nowNew fund, Mar 2025Private equity

GrowthBuyoutAI & Machine LearningArtificial Intelligence & Machine Learning (AI/ML)Asia Private Equity

Deploying now
90%of best year26cheques in 12 months, 148 on record
Since the last cheque24days00hrs00min00sec
Median round$81MRounds led4 of 148Sole investor27 roundsExits1 from the portfolioMostly inUnited States, 78%
Pitch Invus

Invus highlights

  1. 01

    26 cheques in the last 12 months

  2. 02

    Mostly Venture and Series B: 55% of its rounds

  3. 03

    Sole investor in 27 rounds, median $21M

  4. 04

    1 exits from the portfolio

What they do

Includes investments in private companies where Invus was the only or the lead investor with $10M+ equity, and where the investment has been fully or partially exited since 1993.From their own website
Type
Private equity
Cheque size
From $10M as they say
Stages
GrowthBuyout
Sectors
AI & Machine LearningArtificial Intelligence & Machine Learning (AI/ML)Asia Private Equity
Based in
New York, United States
Cold pitches
Not accepted

The record

Every round we can evidence, newest first148 appearances

  1. 2026

    21 rounds

  2. Oct
    Matchpoint TherapeuticsSeries B · US · Firms' own news pages$150MWith 9 others
  3. Sept
    EliseAIGrowth · US · TechCrunch$350MWith 6 others
  4. Sept
    Precision NeuroscienceGrowth · US · AlleyWatch$250MWith 12 others
  5. Sept
    Caspian TherapeuticsSeries A · QRM Capital$50MWith 7 others
  6. Sept
    Tyra BiosciencesUS$400MWith 5 others
  7. Sept
    One BiosciencesGrant · FR$3.8MWith 3 others
  8. Sept
    Encoded TherapeuticsSeries F · US$275MWith 4 others
  9. Sept
    WithinVenture · US$70MWith 4 others
  10. Jul
    ErascaUS$633MWith 4 others
  11. Jul
    BRIUSVenture · US$5.0MWith 2 others
  12. Jun
    City TherapeuticsSeries B · US · Ventureburn$100MWith 8 others
  13. Jun
    ContralineSeries B · Ventureburn$93MWith 9 others
  14. Jun
    Osanni BioSeries B · US$190MSole investor
  15. Jun
    Engine BiosciencesVenture · SGUndisclosedWith 2 others
  16. May
    Cartesian TherapeuticsDebt · US$50MSole investor
  17. Apr
    Ray TherapeuticsSeries B · US · 4BIO Capital$125MWith 10 others
  18. Apr
    VeraDermicsUS$384MWith 3 others
  19. Mar
  20. Jan
    RapidoVentureUndisclosedWith 4 others
  21. Jan
    PrognomiQVenture · US$12MWith 4 others
  22. Jan
    Foghorn TherapeuticsUS$50MWith 3 others
  23. 2025

    18 rounds

  24. Dec
    Triana BiomedicinesSeries B · US$120MWith 3 others
  25. Nov
    MaaT PharmaFR$11MWith 3 others
  26. Nov
    Bambusa TherapeuticsVenture · USUndisclosedWith 3 others
  27. Nov
    AiveSeries A · FR$5.2MWith 4 others
  28. Nov
    Ablative SolutionsVenture · US$10MSole investor
  29. Oct
    HemabSeries C · DK$157MWith 3 others
  30. Oct
    VeraDermicsSeries C · US$150MWith 2 others
  31. Oct
    Rani TherapeuticsUS$60MWith 3 others
  32. Oct
    LEXEO TherapeuticsUS$154MWith 4 others
  33. Jul
    Pretzel TherapeuticsVenture · USUndisclosedWith 2 others
  34. May
    BRIUSSeries B · US$20MWith 2 others
  35. Apr
    RainSeries B · US · TechCrunch$75MWith 9 others
  36. Feb
    ClearScoreDebt · GB$38MWith 2 others
  37. Feb
    Bambusa TherapeuticsSeries A · US$90MWith 3 others
  38. Feb
    DorsiaSeries A · US$50MWith 1 other
  39. Jan
    Coave TherapeuticsSeries A · FR · Seroba Life Sciences$33MWith 10 others
  40. Jan
    Leyden LabsNL · Silicon Canals$70MWith 9 others
  41. Jan
    ImvaxVenture · US$29MSole investor
  42. 2024

    17 rounds

  43. Dec
    TascaSeries A · US$48MWith 1 other

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration5 named

BKBryan KimVice President of the GP.iFiling they signed
CTCarmen TatonChief Financial OfficeriForm ADV
LLLeslie Laura LakeVice President, Secretary, TreasureriForm ADV
PJPhilip Joseph BafundoChief Compliance OfficeriForm ADV
SLSacha LainovicManaging Member of the GP.iFiling they signed

We also hold 27 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$16Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
Invus Financial Advisors, LLC
SEC number
CRD 161603

Funds on its Form ADV

23 private funds, $5.8B in gross assets · filed Nov 2024

Private equity 18Hedge 4Private investment vehicle 1

  1. ATM, L.P.Hedge1 investor$1.8B
  2. Invus, L.P.Private investment vehicle2 investors$927M
  3. Invopps V, L.P.Private equity24 investors$371M
  4. Invopps IV, L.P.Private equity18 investors$370M
  5. Invus Opportunities Fund III, L.P.Private equity4 investors$364M
  6. Invopps FT1A, LLCPrivate equity38 investors$238M
  7. Invopps V US, L.P.Private equity21 investors$236M
  8. Avicenna Life SCI Master Fund L.P.Hedge4 investors$205M
  9. Invus Opportunities Fund III US, L.P.Private equity14 investors$196M
  10. Invopps IV US, L.P.Private equity18 investors$190M

And 13 more on the filing.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

NetcontinuumBought by Barracuda NetworksUndisclosedSept 2007

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Invus. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Invus put money into.

Quick answers about Invus

What does Invus invest in?

Invus invests most often at Venture and Series B (55% of the rounds on record), in sectors such as AI & Machine Learning, Artificial Intelligence & Machine Learning (AI/ML) and Asia Private Equity.

How active is Invus?

148 investments on record, 26 of them in the last 12 months, and it led 4. The most recent was in Oct 2026.

What has Invus invested in recently?

Its most recent investments on record: Matchpoint Therapeutics (Series B, Oct 2026), EliseAI (Growth, Sept 2026) and Precision Neuroscience (Growth, Sept 2026).

How big are Invus's cheques?

The median round it joins is $81M.

Does Invus lead rounds?

Sometimes: it led 4 of its 148 investments on record (3%).

Where does Invus invest?

Most of the companies it backs are in the United States (78%) and France (11%).

Is Invus investing now?

Yes: it is actively investing, with 26 investments in the last 12 months.

Who does Invus invest alongside?

Most often RA Capital Management (15 rounds together), Fidelity (11 rounds together) and Janus Henderson Investors (10 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it